海翔药业：公司为全球头部药企和国内头部药企的临床三期创新药提供原料药及中间体CMO/CDMO服务

证券之星2025-07-16

证券之星消息，海翔药业(002099)07月16日在投资者关系平台上答复投资者关心的问题。

投资者提问：请问公司创新药涉及哪些方面呢

海翔药业回复：您好，公司为数个全球头部药企和国内头部药企的临床三期创新药提供原料药及中间体CMO/CDMO服务，涵盖降糖、抗感染等领域。此外公司投资设立的产业基金参投项目涉及HPV感染及肝癌治疗性疫苗、TCR-T细胞治疗、重组巴曲酶等领域。感谢您对公司的关注！

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551128145?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-16 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551128145","market":"fut","top_or_hot":-1,"title":"海翔药业：公司为全球头部药企和国内头部药企的临床三期创新药提供原料药及中间体CMO/CDMO服务","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/002099\">海翔药业</a>(002099)07月16日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：请问公司创新药涉及哪些方面呢</p><p>海翔药业回复：您好，公司为数个全球头部药企和国内头部药企的临床三期创新药提供原料药及中间体CMO/CDMO服务，涵盖降糖、抗感染等领域。此外公司投资设立的产业基金参投项目涉及HPV感染及肝癌治疗性疫苗、TCR-T细胞治疗、重组巴曲酶等领域。感谢您对公司的关注！</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海翔药业：公司为全球头部药企和国内头部药企的临床三期创新药提供原料药及中间体CMO/CDMO服务</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海翔药业：公司为全球头部药企和国内头部药企的临床三期创新药提供原料药及中间体CMO/CDMO服务\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-16 16:24 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2025071600025717.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，海翔药业(002099)07月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司创新药涉及哪些方面呢海翔药业回复：您好，公司为数个全球头部药企和国内头部药企的临床三期创新药提供原料药及中间体CMO/CDMO服务，涵盖降糖、抗感染等领域。此外公司投资设立的产业基金参投项目涉及HPV感染及肝癌治疗性疫苗、TCR-T细胞治疗、重组巴曲酶等领域。感谢您对公司的关注！以上内容为...</p>\n\n<a href=\"https://stock.stockstar.com/RB2025071600025717.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://stock.stockstar.com/RB2025071600025717.shtml","article_id":"2551128145","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551128145","pubTimestamp":1752654267,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，海翔药业(002099)07月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司创新药涉及哪些方面呢海翔药业回复：您好，公司为数个全球头部药企和国内头部药企的临床三期创新药提供原料药及中间体CMO/CDMO服务，涵盖降糖、抗感染等领域。此外公司投资设立的产业基金参投项目涉及HPV感染及肝癌治疗性疫苗、TCR-T细胞治疗、重组巴曲酶等领域。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","BK0028":"国家队","BK0239":"医药制造","002099":"海翔药业","BK0192":"染料","BK0188":"融资融券","06978":"永泰生物-B","BK1161":"生物科技","BK1574":"生物医药B类股","BK0077":"质押式回购"},"translate_title":"Haixiang Pharmaceutical: The company provides API and intermediate CMO/CDMO services for clinical phase III innovative drugs of global leading pharmaceutical companies and domestic leading pharmaceutical companies","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"002099":1,"06978":1},"content_text":"证券之星消息，海翔药业(002099)07月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司创新药涉及哪些方面呢海翔药业回复：您好，公司为数个全球头部药企和国内头部药企的临床三期创新药提供原料药及中间体CMO/CDMO服务，涵盖降糖、抗感染等领域。此外公司投资设立的产业基金参投项目涉及HPV感染及肝癌治疗性疫苗、TCR-T细胞治疗、重组巴曲酶等领域。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551128145","isCrawlerRequest":true}